TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34873023
Drug: PENG group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PENG group (20 mL 0.5% ropivacaine)
Study: 34873023
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (20 mL saline)
Study: 35711147
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (3 mg/kg)
Study: 35711147
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (4 mg/kg)
Study: 35711147
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (6 mg/kg)
Study: 35711147
Drug: Reference voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference voriconazole (3 mg/kg)
Study: 35711147
Drug: Reference voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference voriconazole (4 mg/kg)
Study: 35711147
Drug: Reference voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference voriconazole (6 mg/kg)
Study: 32574009
Drug: Tretinoin cream
Normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin cream (0.025%, 0.05%, 0.1%)
Study: 35684089
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (25 g) and Vitamin D3 (4000 IU) before bedtime
Study: 35684089
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (25 g) and Vitamin D3 (4000 IU) after sleeping
Study: 35684089
Drug: Maltodextrin placebo
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin placebo (5 g) - Control group
Study: 35107694
Drug: Higher intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher intervention dosage
Study: 35318229
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Methotrexate and Adalimumab
Study: 32178640
Drug: Therapist guided
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist guided internet-delivered cognitive therapy (TG-iConquerFear)
Study: 32178640
Drug: Augmented treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented treatment as usual (aTAU)
Study: 33276704
Drug: LT4/LT3 combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: LT4/LT3 combination therapy
Study: 35126618
Drug: nano‐Pueraria targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: nano‐Pueraria targeted preparation + Tuina therapy
Study: 35153118
Drug: Cold water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold water spray (0.4 mL per application, twice every hour)
Study: 35153118
Drug: Cold saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold saline spray (0.4 mL per application, twice every hour)
Study: 35153118
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (water at room temperature, 1-2 mL using a syringe)
Study: 32898082
Drug: Topical vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical vancomycin powder at wound closure
Study: 34153729
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (MP) 40 mg twice daily for 7 days
Study: 34153729
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (MP) plus tocilizumab (400 mg single dose)
Study: 33566105
Drug: Personalized weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Personalized weekly coupons with nutrition education during the intervention period (A)
Study: 33566105
Drug: Personalized weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Personalized weekly coupons with nutrition education during the crossover intervention period (A)
Study: 32461420
Drug: 0.5% CMC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% CMC + 2000 IU vitamin D through buccal spray (Group B)
Study: 32461420
Drug: 0.5% CMC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% CMC + 2000 IU vitamin D through buccal spray + 0.05% cyclosporine (Group C)
Study: 36368748
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted cognitive behavioural therapy in a group setting (CA-CBT+)
Study: 32076819
Drug: Oxytocin (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (24 international units, intranasal application)
Study: 34431029
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with antidepressants for 3 weeks
Study: 34431029
Drug: Antidepressants monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants monotherapy for 3 weeks
Study: 36331670
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg morphine sulfate ODT
Study: 36331670
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg morphine sulfate ODT
Study: 36331670
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg morphine sulfate tablet (Sevredol®)
Study: 36331670
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg morphine sulfate tablet (Sevredol®)
Study: 36331670
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg morphine sulfate capsule (Actiskenan®)
Study: 36331670
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg morphine sulfate solution (Oramorph®)
Study: 36331670
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg and 10 mg ODTs and tablets
Study: 34226073
Drug: Nebulized ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized ketamine 0.75 mg/kg
Study: 34226073
Drug: Nebulized ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized ketamine 1 mg/kg
Study: 34226073
Drug: Nebulized ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized ketamine 1.5 mg/kg
Study: 33140457
Drug: PHY906 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHY906 plus capecitabine (750 mg/m2 capecitabine b.i.d. for 14 days and 800 mg of PHY906 b.i.d. on days 1–4 and days 8–11 every 21-day cycle)
Study: 35049373
Drug: 3% diquafosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% diquafosol ophthalmic solution, 1 drop, 6 times per day for 4 weeks
Study: 33045402
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (loading dose, then 3200 IU/day)
Study: 33106180
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metoclopramide, ceftriaxone, and paracetamol
Study: 35482522
Drug: School-based interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based interventions (including cognitive behavioural therapy)
Study: 35482522
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) based interventions
Study: 33070053
Drug: Gefitinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib plus olaparib (250 mg gefitinib daily + 200 mg olaparib three times daily)
Study: 33070053
Drug: Gefitinib alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib alone (250 mg daily)
Study: 35473740
Drug: Low-dose prophylactic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prophylactic anticoagulation (PA)
Study: 35473740
Drug: High-dose prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prophylactic anticoagulation (HD-PA)
Study: 35473740
Drug: Low-dose PA,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose PA, HD-PA, or TA (combined)
Study: 34286397
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids capsule along with standard care
Study: 34255034
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg cholecalciferol daily for 12 weeks (with UVB exposure)
Study: 34255034
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg cholecalciferol daily for 12 weeks (without UVB exposure)
Study: 34255034
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg cholecalciferol (both groups)
Study: 34255034
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg cholecalciferol
Study: 35760910
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg daily
Study: 33059607
Drug: Vi-diphtheria toxoid
Normalized name: DIPHTHERIA TOXOID
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi-diphtheria toxoid typhoid conjugate vaccine (Vi-DT)
Study: 33059607
Drug: Vi-polysaccharide vaccine
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi-polysaccharide vaccine (Vi-PS)
Study: 36443713
Drug: 82Rb PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 82Rb PET/CT after amino acid-infusion
Study: 36443713
Drug: 82Rb PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 82Rb PET/CT before amino acid-infusion (baseline)
Study: 36117055
Drug: Oral treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral treprostinil (TRE)
Study: 35340949
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg nalbuphine (group N)
Study: 35340949
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg fentanyl (group F)
Study: 32172198
Drug: Korean red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean red ginseng (KRG) 2000 mg/day
Study: 32594478
Drug: Internet Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet Behavior Therapy (IBT, n=51)
Study: 35685573
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg/day for eight weeks)
Study: 35685573
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received standard treatment for analgesia (oral diclofenac 75 mg/12 h as needed)
Study: 34770611
Drug: Concurrent visual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent visual feedback
Study: 34770611
Drug: Removal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removal of concurrent feedback
Study: 34770611
Drug: Concurrent vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent vs Terminal feedback
Study: 32833475
Drug: Cognitive bias
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive bias modification training (CBMT) intervention delivered via an 8-session, at-home, electronic tablet.
Study: 34664109
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg CBD, 5.4 mg THC, and 6.6 mg CBC daily
Study: 34664109
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg CBD, 10.8 mg THC, and 13.2 mg CBC daily
Study: 34664109
Drug: 360 mg
Normalized name: aspirin 360 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg CBD, 16.2 mg THC, and 19.8 mg CBC daily
Study: 34664109
Drug: 480 mg
Normalized name: magaldrate 480 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 mg CBD, 21.6 mg THC, and 26.4 mg CBC daily
Study: 34664109
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of CBD, THC, and CBC
Study: 32600393
Drug: Histamine-2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine-2 receptor antagonist (H2RA)
Study: 33299898
Drug: Second IVIG
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second IVIG treatment
Study: 36194219
Drug: Opioid-sparing protocol
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid-sparing protocol (naproxen, acetaminophen, pantoprazole, limited hydromorphone, educational infographic)
Study: 36194219
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (opioid analgesic)
Study: 32702101
Drug: Meloxicam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (15 mg per day) for 4 weeks followed by 10 weeks of meloxicam
Study: 35318752
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant with immediate provisional restoration and socket preservation
Study: 35318752
Drug: Early implant
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early implant placement with guided bone regeneration and delayed loading
Study: 32324435
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg intravenously on days 1 and 15, surgery planned on day 29.
Study: 32890015
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.9% saline infusion)
Study: 35695753
Drug: Intrathecal 2-chloroprocaine
Normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal 2-chloroprocaine 40 mg in Group 1
Study: 35695753
Drug: Intrathecal 2-chloroprocaine
Normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal 2-chloroprocaine 35 mg in Group 2
Study: 35695753
Drug: Intrathecal 2-chloroprocaine
Normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal 2-chloroprocaine 45 mg in Group 3
Study: 35695753
Drug: Intrathecal 2-chloroprocaine
Normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal 2-chloroprocaine (varied doses based on CRM)
Study: 33714527
Drug: oAPBI (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: oAPBI (once daily)
Study: 33714527
Drug: tAPBI (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: tAPBI (twice daily)
Study: 32741071
Drug: Oxycodone 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 0.025 mg/kg
Study: 32741071
Drug: Oxycodone 0.050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 0.050 mg/kg
Study: 32741071
Drug: Oxycodone 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 0.075 mg/kg
Study: 32741071
Drug: Oxycodone 0.100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 0.100 mg/kg
Study: 35092948
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (1000 IU tablet)
Study: 33637409
Drug: Tablet computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet computer game (n = 30)
Study: 33637409
Drug: Standard departmental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard departmental preparation (n = 30)
Study: 34649534
Drug: perinatal specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: perinatal specific cognitive behavioural therapy (CBT)
Study: 34660501
Drug: Free oral
Normalized name: CariFree Oral Paste Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free oral HIV self-test kits (HIVST) offered to participants
Study: 34660501
Drug: Free oral
Normalized name: CariFree Oral Paste Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free oral HIV self-test kits (HIVST)
Study: 35817957
Drug: Metformin (425
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (425 mg/d for 2 years, then 850 mg/d for 2 years)
Study: 34029880
Drug: Online psychosocial
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online psychosocial intervention adjunctive to an activity monitor (Fitbit)
Study: 35395953
Drug: Personalized and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized and home-based speech therapy for 8 weeks
Study: 32333541
Drug: Medication (Prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Prednisone acetate, Acyclovir, Vitamin B12, Vitamin B1)
Study: 32776425
Drug: Immune suppression
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune suppression therapy (IST)
Study: 34883037
Drug: Tailored therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored therapy (TT)
Study: 34883037
Drug: PAM-B therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAM-B therapy
Study: 34700258
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy to Prevent Suicide (MBCT-S)
Study: 34877858
Drug: Topical 0.3%
Normalized name: triclosan topical 0.3% topical bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.3% amphotericin B in 30% dimethyl sulfoxide cream
Study: 34877858
Drug: 30% dimethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% dimethyl sulfoxide cream (vehicle cream)
Study: 34270689
Drug: 400 g
Normalized name: Ambi 60 PSE-400 GFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 g of intrusive force per segment (40 g per root)
Study: 34270689
Drug: 200 g
Normalized name: PEG-200 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g of intrusive force per segment (20 g per root)
Study: 33164956
Drug: Neurodevelopmental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodevelopmental treatment (NDT) exercises
Study: 34503682
Drug: IL-2 treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IL-2 treatment in T-cell-deficient mice
Study: 34105231
Drug: Ridge splitting
Normalized name: BLUE RIDGE BLUEBERRY
DrugBank: Blueberry (DB10629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridge splitting with simultaneous implant placement using patient specific guides (PSGs)
Study: 35691565
Drug: Postmenopausal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postmenopausal hormone (PMH) use
Study: 34347860
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg every other week
Study: 35749144
Drug: Helichrysum italicum
Normalized name: HELICHRYSUM ITALICUM WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helichrysum italicum infusion (HI)
Study: 35749144
Drug: Helichrysum arenarium
Normalized name: HELICHRYSUM ARENARIUM WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helichrysum arenarium infusion (HA)
Study: 32332617
Drug: Multifactorial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifactorial intervention (self-management of antihypertensive medication, self-measurement of blood pressure, hypocaloric and low sodium diet, and physical exercise)
Study: 34085115
Drug: Vonoprazan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan (10 mg/day)
Study: 34085115
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (100 mg/day) with additional PPI (either esomeprazole or vonoprazan)
Study: 33764445
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) 400 μg/m2/day for 5 days via intravenous infusion
Study: 33768619
Drug: Nitazoxanide 500
Normalized name: nitazoxanide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide 500 mg twice daily for 24 weeks
Study: 33768619
Drug: Rifaximin 550
Normalized name: rifAXIMin 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 550 mg twice daily for 24 weeks
Study: 35798534
Drug: Ustekinumab (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (intravenous infusion 6 mg/kg at week 0, followed by subcutaneous injections of 90 mg at week 8 and every 8 weeks)
Study: 36041126
Drug: MSC suspension
Normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSC suspension added to the graft (Group 2)
Study: 35943745
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine (2.0 μg/kg)
Study: 34385543
Drug: Durvalumab and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab and pomalidomide combination therapy
Study: 36301724
Drug: Propofol‐based total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol‐based total intravenous anesthesia (TIVA)
Study: 32684486
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO, 6 g fish oil, 3.85 g EPA & DHA)
Study: 32684486
Drug: Coconut oil
Normalized name: Coconut Oil
DrugBank: Coconut oil (DB14322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coconut oil + fish oil (COFO, 18.65 g coconut oil, 15 g MCSFA + 6 g fish oil, 3.85 g EPA & DHA)
Study: 32684486
Drug: Coconut oil
Normalized name: Coconut Oil
DrugBank: Coconut oil (DB14322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coconut oil (CO, 18.65 g coconut oil, 15 g MCSFA)
Study: 34061883
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment delivered by multidisciplinary teams at opioid agonist treatment clinics or community care centers, including on-site testing for HCV, liver fibrosis assessment, counseling, treatment, and posttreatment follow-up.